Loading
Tandem Diabetes Care Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 11 Aug 2025.
Tandem Diabetes Care Inc: what insiders have been doing
Tandem Diabetes Care Inc, founded in 2008, is a Healthcare & Pharma company based in San Diego, United States. Its directors and officers file their transactions with SEC (Form 4). Over the twelve months to 18 October 2026, 58 filings were filed, from 11 insiders.
No insider bought on the market over the period, while 1 insider filed 1 sale totalling €39. At €39, the sale published on 9 March 2026 by Novara Mark David is the largest of the period.
With 58 filings in twelve months, the company is more active than the median of 22 filings across the 5,458 companies we follow on the same exchange. The full history, which starts in 2016, counts 14 purchases against 16 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 1.01 bn USD and net income at -204.7 m USD.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
410
Thresholds
n/a
Buy Volume
€1M
14 ops. · all time
Sell Volume
€10M
16 ops. · all time
Who traded when
BuySaleNovara Mark David1 buy1 sale
Blickenstaff Kim d1 sale
Jean-Claude Kyrillos1 buy
John F. Sheridan1 buy
Leigh Vosseller1 buy
Since the insiders bought
- +111.1%Entry US$11.10 · Close at T+365 US$23.44
- +111.1%Entry US$11.10 · Close at T+365 US$23.44
- +11.2%Entry US$18.77 · Close at T+365 US$20.87
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Tandem Diabetes Care Inc Buy (bullish), based on 21 analysts. Average price target: US$27.76.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,763 of 24,148 companies
22.1
score / 100
Value14
Quality30
FCF yld-9.6%
Earn yld-18%
EV/EBITDA·
ROE-48%
Gross mgn54%
Net mgn-20%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$16.24
Analyst consensus
21 analystsBuy
US$18.00Target US$27.76(+71%)US$50.00
Income statement
RevenueUS$1B
Gross profitUS$546M54% margin
EBITDA-US$176.6M-17% margin
Net income-US$204.7M-6.1% margin
Valuation
PER (forward)102.2x
P/Book8.7x
Beta1.66
Balance sheet & cash
Market capUS$1.1B
Total debtUS$444.5M
Free Cash Flow-US$108.3M
Debt / Equity567%
Profitability & ownership
ROE-48.0%
ROA-2.6%
% insiders1.2%
% institutions115.6%
Last declaration on 17 September 2026
Declarations410 total
360 shares@ US$17.530.0004% mcap41.5% of flowCommonSEC144:0001950047-26-009635
131 shares@ US$22.2550.0002% mcap19.0% of flowCommonSEC144:0001950047-26-008325
5,982 shares0Common StockSEC:0001438133-26-000131:0
3,044 shares@ US$22.720.0062% mcap12.4% of flowCommon StockSEC:0001438133-26-000131:1
9,934 shares0Common StockSEC:0001438133-26-000131:2
5,055 shares@ US$22.720.010% mcap20.5% of flowCommon StockSEC:0001438133-26-000131:3
1,496 shares0Common StockSEC:0001438133-26-000132:0
537 shares@ US$22.720.0011% mcap1.0% of flowCommon StockSEC:0001438133-26-000132:1
2,624 shares0Common StockSEC:0001438133-26-000132:2
942 shares@ US$22.720.0019% mcap1.8% of flowCommon StockSEC:0001438133-26-000132:3
820 shares@ US$22.720.0017% mcap19.7% of flowCommon StockSEC:0001438133-26-000127:3
897 shares0Common StockSEC:0001438133-26-000127:0
457 shares@ US$22.720.0009% mcap11.0% of flowCommon StockSEC:0001438133-26-000127:1
1,610 shares0Common StockSEC:0001438133-26-000127:2
1,097 shares0Common StockSEC:0001438133-26-000128:0
589 shares@ US$22.720.0012% mcap0.8% of flowCommon StockSEC:0001438133-26-000128:1
1,917 shares0Common StockSEC:0001438133-26-000128:2
1,029 shares@ US$22.720.0021% mcap1.4% of flowCommon StockSEC:0001438133-26-000128:3
1,097 shares0Common StockSEC:0001438133-26-000126:0
1,917 shares0Common StockSEC:0001438133-26-000126:2
1,010 shares0Common StockSEC:0001438133-26-000129:0
1,097 shares0Common StockSEC:0001438133-26-000130:0
314 shares@ US$22.720.0006% mcap0.8% of flowCommon StockSEC:0001438133-26-000130:1
1,730 shares0Common StockSEC:0001438133-26-000130:2
559 shares@ US$22.720.0011% mcap10.2% of flowCommon StockSEC:0001438133-26-000126:1
25 of 410 declarations
About Tandem Diabetes Care Inc
Tandem Diabetes Care, Inc. is a U.S.-based medical technology company listed on the Nasdaq under the ticker TNDM, in the United States market. The company focuses on insulin delivery systems and broader diabetes management technologies. It designs, manufactures, and commercializes durable insulin pumps, automated insulin delivery software, associated consumables, and digital tools used by patients and healthcare professionals. From an investor’s perspective, Tandem is a specialized medtech name with exposure to a high-regulation but innovation-driven market, where product differentiation and recurring usage matter materially.
Founded in 2006, Tandem Diabetes Care is headquartered in San Diego, California. Over time, the company built its franchise around a software-oriented pump platform and strong interoperability with continuous glucose monitoring (CGM) sensors. Its core products include the t:slim X2 insulin pump, the Tandem Mobi platform, and the Control-IQ / Control-IQ+ automated insulin delivery systems, which help adjust insulin delivery based on glucose readings. Tandem also offers Tandem Source, a diabetes management platform for customers and healthcare providers, as well as infusion sets and other related supplies. The company’s strategy combines hardware, software, and consumables into a broader diabetes care ecosystem.
Read moreShow less
Competitively, Tandem operates in a field dominated by larger peers such as Medtronic and Insulet, while also competing indirectly with broader diabetes technology ecosystems. Its market position is built on ease of use, software sophistication, and sensor integration. Management has consistently emphasized a growing worldwide installed base, strong customer retention, and improving commercial execution. The company’s revenue base remains primarily U.S.-driven, but international sales are meaningful and the firm has been expanding beyond the domestic market, including direct commercial operations in select European countries. In 2025, Tandem highlighted continued progress in Europe and further expansion of its global product reach.
Recent developments point to a company in transition from pure growth to a more balanced growth-and-profitability story. In 2025, Tandem reported record sales, gross margin improvement, and several important portfolio milestones: integration of t:slim X2 with Abbott’s FreeStyle Libre 3 Plus CGM, broader pharmacy coverage for Tandem Mobi, and additional regulatory filings with the FDA. It also received FDA clearance to extend Control-IQ+ to adults with type 2 diabetes. In February 2026, the company reported full-year 2025 results showing worldwide sales above $1.0 billion, underscoring stronger execution and scale. For equity investors, Tandem offers a focused U.S. Nasdaq-listed exposure to diabetes technology, with product innovation, regulatory milestones, and geographic expansion as the key drivers to watch.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
